Table 2 Intraventricular pressure measurements.

From: Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis

 

Sham (n = 10)

Control (n = 10)

MKEY (n = 10)

P value (*control)

Basal

Dobutamine

Basal

Dobutamine

Basal

Dobutamine

Developed Pressure (mmHg)

94.9 ± 6.38

145.5 ± 12.21

70.1 ± 3.68

91.3 ± 4.32

96.9 ± 8.65*

127 ± 11.1

<0.05

dPdt max (mmHg/s)

6357 ± 624

13569 ± 713

3138 ± 232

7093 ± 755

4911 ± 440*

11480 ± 644

<0.05

dPdt min (mmHg/s)

−4595 ± 667

−7795 ± 461

−2850 ± 181

−5121 ± 616

−4302 ± 425*

−6611 ± 285

<0.05

Heart rate (bpm)

235 ± 17

414 ± 30

223 ± 11

387 ± 19

221 ± 10

425 ± 22

ns

  1. dP/dtmax: the increase in left ventricle pressure change as measure of contraction; dP/dtmin: the decrease in left ventricle pressure change as measure of relaxation; ns: no significance.
Back to article page